CompoAtlas

Progressive Phytoberry Protein Vanilla Berry Swirl

Natural health product licensed in Canada

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Solanum lycopersicum

Source : Chair (fruit)

Potency : 5 Pour cent Lycopene

5 milligrammeNot calculated
Carica papaya

Source : Fruit

15 milligrammeNot calculated
Rubus idaeus

Source : Fruit

70 milligrammeNot calculated
Sambucus nigra

Source : Fruit

35 milligrammeNot calculated
Camellia sinensis

Source : Feuille

Potency : 50 Pour cent Polyphenols

35 milligrammeNot calculated
Betula pubescens

Source : Feuille

50 milligrammeNot calculated
3,3',4',5,7-Pentahydroxyflavone

Source : Styphnolobium japonicum - fleur

5 milligrammeNot calculated
Acide DL-alpha-lipoïque

Source : Acide DL-alpha-lipoÏque

15 milligrammeNot calculated
Garcinia mangostana

Source : Fruit

200 milligrammeNot calculated
Lécithine

Source : Glycine max - Graine

900 milligrammeNot calculated
Phyllanthus emblica

Source : Fruit

215 milligrammeNot calculated
Punica granatum

Source : Fruit

300 milligrammeNot calculated
Isolat de protéine de lactosérum

Source : Bos taurus (lait)

Potency : 92 Pour cent Whey protein

4 gNot calculated
Zea mays

Source : Styles et stigmates

15 milligrammeNot calculated
Lycium barbarum

Source : Fruit

1,200 milligrammeNot calculated
Vaccinium macrocarpon

Source : Fruit

140 milligrammeNot calculated
Vitis vinifera

Source : Fruit

Extraction ratio : 8:1

Dry plant equivalent : 120 mg

15 milligrammeNot calculated
Vitis vinifera

Source : Graine(s)

Potency : 85 Pour cent Proanthocyanidins

15 milligrammeNot calculated
Linum usitatissimum

Source : Linum usitatissimum - Graine

260 milligrammeNot calculated
Euterpe oleracea

Source : Fruit

600 milligrammeNot calculated

Non-medicinal ingredients

Betterave rouge, Saveur, Feuille de Stevia rebaudiana, Huile essentielle d'écorce de Cannelier de Ceylan, Maltodextrine, evaporated cane juice, Essences de thym, Huile essentielle de romarin, Saveur de baies, Gomme de Guar, Saveur de vanille, Essence de girofle, Huile essentielle de pelure de Citrus Aurantium Dulcis (Orange), Extrait de Raisin, Huile essentielle de feuilles d'Origanum Vulgare

PopulationAgeQuantity per servingFrequency
AdultesNot specified1 Mesures1 Tous les jours

Uses authorised in Canada

Source of essential amino acids for the maintenance of good health. Source of antioxidants for the maintenance of good health. Provides antioxidants for the maintenance of good health. Source of essential fatty acids for the maintenance of good health. Source of omega-3 fatty acids for the maintenance of good health. Source of alpha-linolenic acid (ALA) for the maintenance of good health.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Product record

Licence holder
Jamieson Laboratories Ltd./ Nutricorp International
NPN or DIN-HM
80041947
Status
Active licence
Licence date
26 April 2013
Revision date
8 September 2026
Form
Poudre
Route of administration
Orale
Application type
Non traditionnelle

Source

Official Health Canada record, licence 80041947

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Sambucus nigra
    Read the warning, when it applies and the studies cited

    ELDER – SAMBUCUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condition of application: Diaphoretic; Symptoms of colds, flus; Sinusitis, hay-fever; Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occur (Forster-Waldl et al. 2003).

    Sources cited by Health Canada (1)
    • Förster-Waldl E, Marchetii M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Jäger S, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Type I allergy to elderberry (Sambucus nigra) is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins. Clinical and Experimental Allergy 2003;33(2):1703-1710. PubMed

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur (Bradley 1992; Winston and Kuhn 2008; Barnes et al. 2007; Hoffman 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd edition. London (GB): The Pharmaceutical Press; 2007.
    • Winston D and Kuhn MA. Herbal Therapy & Supplements A Scientific and Traditional Approach. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Betula pubescens
    Read the warning, when it applies and the studies cited

    Birch

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney or cardiovascular disorders (Brinker 2010; Bradley 2006; ESCOP 2003; Blumenthal et al. 1998).

    Sources cited by Health Canada (4)
    • Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Riggins C, Rister R, editors. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin (TX): American Botanical Council; 1998.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    Sources cited by Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Health Canada monograph dated 28 August 2024

  • Lécithine
    Read the warning, when it applies and the studies cited
  • Phyllanthus emblica
    Read the warning, when it applies and the studies cited

    Amla - Phyllanthus Emblica

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Sources cited by Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Applies to products providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Sources cited by Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Condition of application: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Sources cited by Health Canada (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Contraindications

    Condition of application: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Sources cited by Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Known adverse reactions

    Condition of application: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Health Canada monograph dated 28 March 2025

  • Punica granatum
    Read the warning, when it applies and the studies cited
  • Vaccinium macrocarpon
    Read the warning, when it applies and the studies cited

    CRANBERRY - VACCINIUM MACROCARPON

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    DRIED CRANBERRY JUICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Sources cited by Health Canada (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Sources cited by Health Canada (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Condition of application: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

  • Linum usitatissimum
    Read the warning, when it applies and the studies cited

    FLAXSEED - LINUM USITATISSIMUM

    Route of administration: Oral

    Cautions and warnings

    Applies to products providing 5 g or more of flaxseed per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).

    Sources cited by Health Canada (1)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).

    Sources cited by Health Canada (2)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Condition of application: Laxative; Promotion of bowel movement; Constipation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    Sources cited by Health Canada (2)
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
    • Repchinsky 2002: Canadian Pharmacists Association. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.

    Contraindications

    Applies to products providing 5 g or more of flaxseed per day.

    Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).

    Sources cited by Health Canada (2)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).

    Sources cited by Health Canada (4)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Gardner Z. and McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. American Herbal Products Association. Boca Raton (FL): CRC Press; 2013.

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).

    Sources cited by Health Canada (2)
    • EMA 2015. European Medicines Agency. European Union Herbal Monograph on Linum usitatissimum L., semen. London (GB): EMA Committee on Herbal Medicinal Products (HMPC), 10 March 2015. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-linum-usitatissimum-l-semen_en.pdf
    • León F, Rodríguez M, Cuevas M. 2003. Anaphylaxis to Linum. Allergologia et immunopathologia 31(1):47-49.

    Health Canada monograph dated 26 July 2024

  • Euterpe oleracea
    Read the warning, when it applies and the studies cited

    ACAI – EUTERPE OLERACEA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (derMarderosian and Beutler 2008).

    Sources cited by Health Canada (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (derMarderosian and Beutler 2008).

    Sources cited by Health Canada (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Health Canada monograph dated 24 April 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Progressive Phytoberry Protein Vanilla Berry Swirl (Jamieson Laboratories Ltd./ Nutricorp International): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80041947-progressive-phytoberry-protein-vanilla-berry-swirl, updated 8 September 2026.

Enter to analyse, Shift+Enter for a new line